Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.43 |
| ▸ | BRD4 | O60885 | 2/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.43 |
| ▸ | CDK4 | P11802 | 6/20 | 0.43 |
| ▸ | CDK6 | Q00534 | 5/20 | 0.43 |
| ▸ | WEE1 | P30291 | 6/20 | 0.42 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.40 |
| ▸ | INSR | P06213 | 1/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL188054 | 1.00 | JAK2 (0.43) | JAK2BRD4FGFR4CDK4CDK6 | |
| SCHEMBL8513235 | 0.94 | WEE1 (0.42) | CDK4CDK6WEE1PLK1 | |
| SCHEMBL8513021 | 0.89 | PIK3CD (0.44) | JAK2BRD4CDK4CDK6WEE1 | |
| SCHEMBL8510633 | 0.85 | ADRA2A (0.46) | WEE1PLK1 | |
| SCHEMBL8512238 | 0.85 | ADRA2A (0.46) | WEE1PLK1 | |
| SCHEMBL214554 | 0.85 | WEE1 (0.53) | CDK4CDK6WEE1PLK1ALK | |
| SCHEMBL9609434 | 0.84 | WEE1 (0.41) | CDK4WEE1PLK1EGFRZAP70 | |
| SCHEMBL8513269 | 0.84 | WEE1 (0.44) | WEE1PLK1ZAP70 | |
| SCHEMBL8513478 | 0.84 | WEE1 (0.44) | WEE1PLK1ZAP70 | |
| SCHEMBL8514564 | 0.83 | WEE1 (0.51) | FGFR4CDK4WEE1PLK1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288396-B2 | Pyrimidopyrimidoindazole derivative | MSDKK (JP) | 2012-10-16 | — | — | US | disclosed |
| US-8288396-B2 | Pyrimidopyrimidoindazole derivative | MSDKK (JP) | 2012-10-16 | — | — | US | disclosed |
| US-8288396-B2 | Pyrimidopyrimidoindazole derivative | MSDKK (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | WEE1, WEE2, DCK | JAK2 137/4885BRD4 1149/4885FGFR4 1631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.